Ricardo Rocha

TL;DR: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril–valsartan therapy led to a greater reduction in the N‐terminal pro–B‐type natriuretic peptide concentration than enalapril therapy.

TL;DR: This exploratory study of patients with heart failure and reduced ejection fraction treated with sacubitril-valsartan found a correlation between changes in log2-NT-proBNP concentrations and left ventricular (LV) EF,LV end-diastolic volume index (LVEDVI), LV end-systolic volumeIndex (LVESVI), left atrial volume index(LAVI), and ratio of early transmitral Doppler velocity/early diastolic

TL;DR: Great reductions from baseline were seen with sacubitril-valsartan than with enalapril in all others, including left atrial volume and left ventricular end-systolic and end-diastolic volume indexes (LVESVI and LVEDVI), and ventricular-vascular coupling ratio.

TL;DR: High doses of valsartan reduced albuminuria more than the more commonly used 160 mg dose, apparently independent of blood pressure, suggesting that at least in type 2 diabetes mellitus, higher doses are required to optimize tissue protection than for blood pressure control.

TL;DR: The primary results of the randomized double-blind PIONEER-HF trial were reported demonstrating that, in comparison with enalapril, in patients hemodynamically stabilized during hospitalization for ADHF, sacubitril/ valsartan achieved a greater reduction in N-terminal pro-brain natriuretic peptide concentration, was safe and well-tolerated.